The quest to develop an effective therapy for neuroblastoma.

Area of Science:

• Pediatric Oncology
• Cancer Biology
• Genetics

Background:

• Neuroblastoma (NB) is a prevalent extracranial solid tumor in children, originating from neural crest cells.
• NB exhibits variable behavior, from spontaneous regression to aggressive metastasis and treatment resistance.
• Understanding NB's molecular landscape, including genomic, epigenomic, and transcriptomic alterations, is key.

Purpose of the Study:

• To review the current understanding of neuroblastoma staging.
• To discuss the biological and genetic features influencing NB behavior.
• To explore current and emerging therapeutic strategies for NB.

Main Methods:

• Review of existing literature on neuroblastoma.
• Analysis of molecular characteristics, including MYCN amplification.
• Examination of clinical staging, risk stratification, and treatment approaches.

Main Results:

• MYCN oncogene amplification is a hallmark of high-risk NB.
• Improved risk stratification based on biological and clinical factors aids treatment planning.
• Multicomponent therapeutic approaches are necessary for high-risk and relapsed NB.

Conclusions:

• Accurate staging and risk assessment are vital for effective neuroblastoma management.
• Novel therapies, including targeted chemotherapy, radiation, and immunotherapy, are needed.
• Continued research into NB biology is essential for improving pediatric patient survival rates.